The Effect of oxytocin on clinical signs, ACTH & cortisol levels and methamphetamine craving in matrix maintenance treatment
- Conditions
- Drug abuse.Drug abuse counseling and surveillance
- Registration Number
- IRCT20171129037673N1
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 50
18-65 years old
Male
Methamphetamine dependency as assessed by the substance abuse section of the Structured Clinical Interview of DSM-IV
Being at the Matrix Model of treatment.
Seeking treatment for methamphetamine use
Patients willing to participate in the intervention
Suicide attempts within the past 12 months; suicidal ideas or psychotic symptoms in the past 6 months determined by a study team physician
Current opioid, alcohol or sedative physical dependence or cocaine dependence
Major cardiovascular disorder
Abnormal liver function
Having severe psychotic disorders
Metabolic diseases such as diabetes
Neurological diseases
Positive urine tests indicating abuse of any substance or stimulant
Unwillingness to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measure of desire for methamphetamine. Timepoint: Complete questionnaire weekly. Method of measurement: CCQ-Brief Questionnaire.;Depression beck score. Timepoint: Complete questionnaire weekly. Method of measurement: Questionnaire.;Anxiety beck score. Timepoint: Complete questionnaire weekly. Method of measurement: Questionnaire.;ACTH level in the blood plasma. Timepoint: Before, middle and end of study. Method of measurement: Blood screening.;Cortisol level in the blood plasma. Timepoint: Before, middle and end of study. Method of measurement: Blood screening.
- Secondary Outcome Measures
Name Time Method